NEW YORK (GenomeWeb News) – Seegene announced today that it has signed an agreement with Eidia to market the firm's molecular diagnostic products in Japan.
Under the deal, Eidia, which is the diagnostics subsidiary of Eisai, will have access to Seegene's TOCE (tagging oligonucleotide capture and extension) multiplex molecular diagnostic tests. The Japanese firm will exclusively market and distribute the tests in Japan, and it will seek regulatory clearance from the Japanese Pharmaceutical and Medical Device Agency.
"Our partnership with Eidia opens a significant sales channel for our novel diagnostic tests in Japan," Jong-Yoon Chun, founder, CTO, and CEO of Seegene, said in a statement. "We look forward to working with Eidia to improve patient healthcare with highly sensitive and specific multiplexed MoDx tests."
Further terms of the agreement were not disclosed.